Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SAXJE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
OMTX705
|
|||||
| Synonyms |
OMTX705; IN30705
Click to Show/Hide
|
|||||
| Organization |
Oncomatryx (Originator);InxMed
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
OMTX005
|
Antibody Info | ||||
| Antigen Name |
Prolyl endopeptidase FAP (FAP)
|
Antigen Info | ||||
| Payload Name |
TAM470
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC-PEG3
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
|||||||||
| Colorectal cancer |
1 Trials
|
|||||||||
| Gastric cancer |
1 Trials
|
|||||||||
| Head and neck cancer |
1 Trials
|
|||||||||
| Lung cancer |
1 Trials
|
|||||||||
| Oesophageal cancer |
1 Trials
|
|||||||||
| Ovarian cancer |
1 Trials
|
|||||||||
| Peritoneal cancer |
1 Trials
|
|||||||||
| Pleura mesothelioma |
1 Trials
|
|||||||||
| Sarcomas |
1 Trials
|
|||||||||
| Unspecific solid tumor |
2 Trials
|